Revlamer 800 Tablet

By Revlamer

Rx

10 Tablet in a Strip

Composition icon

Composition

Sevelamer(800mg)

Manufacturer - Sun Pharmaceutical Industries Ltd icon

Manufacturer - Sun Pharmaceutical Industries Ltd

Plot no 107/108,Namli block , Ranipool, East Sikkim 737135

Expires on or after icon

Expires on or after

July, 2027

About Revlamer 800 Tablet

Revlamer 800 Tablet is a medication that falls under the category of phosphate binders, which are designed to lower the amount of phosphate in the body. Specifically, it is utilized to manage high phosphate levels, a condition known as hyperphosphatemia, in adult patients undergoing dialysis or coping with chronic kidney disease. This tablet, containing sevelamer as its active ingredient, operates by binding phosphate within the gastrointestinal tract to reduce absorption. By effectively lowering excessive phosphate levels in the bloodstream, Revlamer 800 Tablet aids in preventing the dangerous accumulation of phosphate, maintaining bone strength, and reducing the risk of heart diseases and strokes.

When taking Revlamer 800 Tablet, it is crucial to follow your doctor's instructions precisely. The recommended dose and duration should be adhered to consistently and at the same time each day to ensure maximum therapeutic benefits. It is essential to consume this medication with food. However, be mindful of potential side effects, which may include nausea, vomiting, abdominal discomfort, constipation, and diarrhea. Additionally, there is a possibility of experiencing low levels of calcium, folic acid, and various vitamins in the bloodstream due to the effects of the tablet. In such cases, it is important to seek guidance from your doctor and take any necessary supplements to address these deficiencies.

Certain precautions should be observed before using Revlamer 800 Tablet. Individuals with a known history of allergies to the components of the medicine, low blood phosphate levels, or bowel obstruction should avoid its usage. Moreover, if you have conditions such as swallowing difficulties, stomach or bowel motility problems, a history of frequent vomiting, inflammatory bowel disease, or have undergone significant abdominal surgery, it is advisable to inform your healthcare provider before starting this medication. Pregnant or breastfeeding individuals should consult their doctor before initiating treatment to ensure its safety and appropriateness for their particular situation. It's worth noting that Revlamer 800 Tablet is not intended for use in children and adolescents under 18 years of age to avoid potential risks and complications.

In summary, Revlamer 800 Tablet serves as a valuable pharmaceutical intervention for managing high phosphate levels in patients with kidney-related issues. Its mechanism of action, coupled with adherence to dosage instructions and necessary precautions, can effectively contribute to regulating phosphate levels, promoting bone health, and reducing the risks associated with elevated phosphate levels in the body.


Disclaimer

The information provided on this website is to the best of our abilities to ensure it is accurate, reliable, and reviewed by a team of professionals. It should not be used to diagnose, prevent, or cure any health problem. The information presented here is not intended to create a doctor-patient relationship or replace a registered medical practitioner's advice, diagnosis, or treatment. The absence or provision of any information or warning regarding any medicine should not be assumed as an implied or explicit assurance of safety or efficacy. We highly recommend consulting your registered medical practitioner for all queries or doubts related to your medical condition. Do not ignore professional medical advice or delay seeking it based on the content encountered on our website. We intend to support, not replace, the doctor-patient relationship.

222

Inclusive of all taxes

Content verified by

chevron-right

Dr. Gowri Kulkarni

MBBS - General Medicine, DNB - Psychiatry, MRCGP [INT] Family Medicine, BSIC (BACP)

Last update on 01-Oct-2024